Neurotoxic Complications of Chemotherapy in Children. Literature Review
https://doi.org/10.15690/pf.v17i1.2077
Abstract
The article provides the review of literature on the issue of neurotoxic complications of chemotherapy in children. The data search was carried out in the PubMed, CyberLeninka, RSCI databases and others. There are many works devoted to studying the distribution, structure, and clinical features of chemo-induced neurological disorders in modern literature. In general, analysis of literature has shown that the incidence of neurotoxic complications varies widely depending on the research methods and used chemo-ther-apeutic drugs. Manifestations of chemotherapy-induced neurological disorders are quite diverse and accompanied by the central and peripheral nervous system damage. However, it has been shown that the platinum-based drugs have effective ototoxic effect with the damage of the auditory nerve. The Vincristine often causes peripheral polyneuropathy. Methotrexate and Ifosfamide cause metabolic encephalopathy. Cytarabine’s neurotoxicity is the damage of the cerebellum. The addition of neurological symptoms leads to decrease in the quality of life of patients. Some studies present the results of study of the causes and pathogenetic manifestations of neurotoxic reactions, changes in the genome associated with the development of specific toxic effects are identified. Despite the fact that many pathogenetic mechanisms of chemotherapy-induced neurotoxic complications have been revealed, the significance of laboratory predictors for prognosing and early assessment of these complications has not been essentially established yet, thus, there is the need for further study of this topic.
Supporting agencies: Not specified
About the Authors
Olga P. Kovtun
Ural State Medical University
Russian Federation
Russian Federation
Ekaterinburg
Vladimir V. Bazarny
Ural State Medical University
Russian Federation
Russian Federation
Ekaterinburg
Oksana V. Koryakina
Ural State Medical University
Russian Federation
Russian Federation
Ekaterinburg
Alexandr N. Abdullaev
Ural State Medical University
Russian Federation
Russian Federation
Ekaterinburg
References
1. Lemiere J, Vercruysse T, Jacobs S, et al. Follow-up study of intellectual functioning in children treated for a brain tumor. Pediatric Blood Cancer. 2014;61(S2):S282-S282.
2. Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol. 2009;63(5):761-767. doi: 10.1007/s00280-008-0876-6.
3. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192-201.
4. Lofstad GE, Reinfjell T, Hestad K, Diseth TH. Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only. Acta Paediatr. 2009; 98(1):180-186. doi: 10.1111/j.1651-2227.2008.01055.x.
5. Stouten-Kemperman MM, de Ruiter MB, Caan MW, et al. Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy. Hum Brain Mapp. 2015;36:4638-4647. doi: 10.1002/hbm.22942.
6. Kuznetsova EI. Neurotoxic the effects of chemotherapy on the function of the central nervous system in children with lymphoid tumors. Pathological physiology and experimental therapy. 2014;58(4):71-77. (In Russ). doi: 10.25557/0031-2991.2014.04.71-77.
7. Mohrmann C, Henry J, Hauff M, Hayashi RJ. Neurocognitive outcomes and school performance in solid tumor cancer survivors lacking therapy to the central nervous system. J Pers Med. 2015;5(2):83-90. doi: 10.3390/jpm5020083.
8. Duffner PK. The long term effects of chemotherapy on the central nervous system. J Biol. 2006;5(7):21. doi: 10.1186/jbiol51.
9. Politova EA, Rumyantsev AG, Zavadenko NN, et al. Neuromuscular complications in the treatment of acute myeloid leukemia. Voprosy prakticheskoy pediatrii. 2015;10(4):15-19. (In Russ).
10. Kelley KW, Bluthe RM, Dantzer R, et al. Cytokine-induced sickness behavior. Brain Behav Immun. 2003;17(1):S112-118. doi: 10.1016/s0889-1591(02)00077-6.
11. Yang M, Kim JS, Kim J, et al. Neurotoxicity of methotrexate to hippocampal cells in vivo and in vitro. Biochem Pharmacol. 2011;82(1):72-80. doi: 10.1016/j.bcp.2011.03.020.
12. Christie LA, Acharya MM, Parihar VK, et al. Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res. 2012;18(7):1954-1965. doi:10.1158/1078-0432.CCR-11-2000.
13. Rzeski W, Pruskil S, Macke A, et al. Anticance1r agents are potent neurotoxins in vitro and in vivo. Ann Neurol. 2004;56(3):351-360. doi: 10.1002/ana.20185.
14. Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev. 2008;18(2):121-131. doi: 10.1007/s11065-008-9058-x.
15. Yan F, Liu JJ, Ip V, et al. Role of platinum DNA damage-induced transcriptional inhibition in chemotherapy-induced neuronal atrophy and peripheral neurotoxicity. J Neurochem. 2015;135(6):1099-1112. doi: 10.1111/jnc.13355.
16. Kim HS, Guo C, Thompson EL, et al. APE1, the DNA base excision repair protein, regulates the removal of platinum adducts in sensory neuronal cultures by NER. Mutat Res. 2015;779:96-104. doi: 10.1016/j.mrfmmm.2015.06.010.
17. Calls A, Carozzi V, Navarro X, et al. Pathogenesis of platinum-induced peripheral neurotoxicity: insights from preclinical studies. Exp Neurol. 2020;325:113141. doi: 10.1016/j.expneu-rol.2019.113141.
18. Adamson P Blaney S, Helman L, et al. Principles and practice of pediatric oncology. 6th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2011.
19. Granowetter L, Rosenstock JG, Packer RJ. Enhanced cis-platinum neurotoxicity in pediatric patients with brain tumors. J Neurooncol. 1983;1(4):293-297. doi: 10.1007/BF00165711.
20. Van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev. 2016;(8):CD010181. doi: 10.1002/14651858.CD010181.pub2.
21. Bertolini P Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004 ;26(10):649-655.
22. Dean JB, Hayashi SS, Albert CM, et al. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol. 2008;30(2):130-134. doi: 10.1097/MPH.0b013e31815d1d83.
23. Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T. A metaanalysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev. 2013;39(3):297-304.
24. Gomber S, Dewan P Chhonker D. Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr. 2010;77(1):97-100. doi: 10.1007/s12098-009-0254-3.
25. Arzanian MT, Mehdizadeh M, Zamani GR. Vincristine induced neurotoxicity: study of 75 cases. Iran J Child Neur. 2009;3(2):39-44.
26. Guram S, Richards E, Messahel B. G21(P) Investigating vincristine neurotoxicity in paediatric haematology/oncology patients: a role for genotyping. Arch Dis Child. 2016;101:A15. doi: 10.1136/archdischild-2016-310863.21.
27. Renbarger JL, McCammack KC, Rouse CE, Hall SD. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer. 2008;50:769-771. doi: 10.1002/pbc.21435.
28. Sims RP The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia. J Oncol Pharm Pract. 2016;22(1):76-81. doi: 10.1177/1078155214553143.
29. Adhikari S, Dongol RM, Hewett Y, Shah BK. Vincristine-induced blindness: a case report and review of literature. Anticanc Res. 2014;(11):6731-6733.
30. Totadri S, Trehan A. Vincristine induced cortical blindness: an alarming but reversible side effect. Pediatr Hematol Oncol J. 2016;1(3):61-62. doi: 10.1016/j.phoj.2016.11.001.
31. Roshchik AS, Kolesnikova OI. Vysokie dozy metotreksata i sistema gemostaza u detei s ostrym limfoblastnym leikozom. Mezhdunarodnyi zhurnal prikladnykh i fundamental’nykh issledovanii. 2014;(1-2):287-287. (In Russ).
32. Vil'chevskaya EV. Toksicheskoe deistvie srednikh doz metotreksata pri lechenii detei, bol'nykh ostrym limfoblastnym leikozom. Onkologiia. 2002;(4):212-214. (In Russ).
33. Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):949-959. doi: 10.1200/JC0.2013.53.0808.
34. Youssef AA, Raafat TA, Madney Y. Child with acute methotrexate related neurotoxicity: Can diffusion weighted MRI help? Egypt J Radiol Nucl Med. 2015;46(4):1149-1153. doi: 10.1016/j.ejrnm.2015.07.015.
35. Fisher MJ, Khademian ZP Simon EM. et al. Diffusion-weighted mr imaging of early methotrexate-related neurotoxicity in children. Am J Neur. 2005;26(7):1686-1689.
36. Di Cataldo A, Astuto M, Rizzo G, et al. Neurotoxicity during ifos-famide treatment in children. Med Sci Monit. 2009;15(1):CS22-25.
37. Lane S, Wilson S. Ifosfamide — induced encephalopathy (guide). TVCN Principal Treatment Centre Children's Hospital Oxford; 2015. Avaliable from: http://tvscn.nhs.uk/wp-content/uploads/2014/09/Cancer-Children-Haematology-Emergencies-Ifosfamide-Induced-Encephalopathy-v3.0-Dec-2015.pdf.
38. Nicolao P Giometto B. Neurological toxicity of ifosfamide. Oncology. 2003;65(Suppl 2):11-16.
39. Tran PN, Kong XT. Cytarabine induced acute cerebellar syndrome during hyper-CVAD treatment for B-cell acute lymphoblastic leukemia. Case Rep Neurol. 2017;9(1):114-120. doi: 10.1159/000468921.
40. Dotson JL, Jamil MO. Successful treatment of cytarabine-related neurotoxicity with corticosteroids, a case series. Int J Hematol. 2018;108(5):554-557. doi: 10.1007/s12185-018-2485-4.
41. Stone JB, De Angelis LM. Cancer treatment-induced neurotoxicity:a focus on newer treatments. Nature Rev Clin Oncol. 2016;13(2):92-105. doi: 10.1038/nrclinonc.2015.152.
42. Sainz de la Maza Cantero S, Jimenez Martin A, de Felipe Mimbrera A, Corral Corral I. Cerebellar toxicity due to cytarabine: a series of 4 cases. Neurologia. 2016;31(7):491-492. doi: 10.1016/j.nrl.2014.12.017.
43. Varghese DR, Joseph D, Prabhu R, Anila KN. High dose cytarabine associated cerebellar toxicity: a case report. Natl J Physiol Pharm Pharmacol. 2018;8(1):142-143.
44. Pellier I, Leboucher B, Rachieru P et al. Flushing out of cerebrospinal fluid as a therapy for acute cerebellar dysfunction caused by high dose of cytosine arabinoside: a case report. J Pediatr Hematol Oncol. 2006;28(12):837-839. doi: 10.1097/MPH.0b013e31802d3e2d.
45. Lowenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013;121(1):26-28. doi: 10.1182/blood-2012-07-444851.
46. Malhotra P Mahi S, Lal V, et al. Cytarabine-induced neurotoxicity responding to methyl prednisolone. Am J Hematol. 2004;77(4):416. doi: 10.1002/ajh.20171.
47. Ibrahim EY, Ehrlich BE. Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings. Crit Rev Oncol Hematol. 2020;145:102831. doi: 10.1016/j.critrev-onc.2019.102831.
Review
For citations:
Kovtun O.P., Bazarny V.V., Koryakina O.V., Abdullaev A.N. Neurotoxic Complications of Chemotherapy in Children. Literature Review. Pediatric pharmacology. 2020;17(1):12-17. (In Russ.) https://doi.org/10.15690/pf.v17i1.2077
Views:
1001
Email this article 